TICKERNERD
Menu
RFLRFLReal Estate · Real Estate Services

RFL Stock Forecast: Rafael Holdings, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.28
−1.54% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Oct 2026 — in the lower half.

Market cap
$67.6M
Ticker Nerd rank
43/ 100
Median analyst target
—
Analysts covering
—
Revenue$179K+132.5% y/y
Operating income−$6.9M
Net income−$2.9M
Free cash flow−$7.3M
Quarterly, 8 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.9%
1M
−36.0%
YTD
+8.5%
1Y
−7.2%
From 52W high
−66.1%
From 52W low
+10.3%
$1.16
$3.78
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RFL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rafael Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
43/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
78
Volatility
70
Momentum
62
Accruals
59
Growth
58
Quality
51
Issuance
33
Value
29
Revisions
25

Size (78): Smaller than most of the companies we track.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RFL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RFL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Jan 26Apr 26Jul 26Oct 26RFL

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RFL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

RFL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Rafael Holdings, Inc. returned −7.2% against +15.6% for the S&P 500, dividends included.

RFL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26RFLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RFL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Rafael Holdings, Inc. (RFL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.3×

Cheaper than 47% of US stocks

Price / sales
69.0×

Cheaper than 4% of US stocks

Price / book
0.9×

Cheaper than 73% of US stocks

EV / EBITDA
−1.2×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−50.6%

Higher than 5% of US stocks

Earnings growth (YoY)
132.5%

Higher than 87% of US stocks

Gross margin
95.5%

Higher than 98% of US stocks

Operating margin
−3838.0%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−37.6%

Higher than 25% of US stocks

Return on assets
−22.8%

Higher than 17% of US stocks

Dividend yield
3944.2%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rafael Holdings, Inc. (RFL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rafael Holdings, Inc. has a market value of $67.6M and an enterprise value of $43.1M.

  • Revenue in the twelve months to 30 Apr 2026: $992K. The latest quarter shrank 50.6% year on year.

  • Net income over the same four quarters: −$23.1M, a −2325.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.59.

  • Free cash flow in the twelve months to 30 Apr 2026: −$24.8M, after $72K of capital spending.

  • Shares outstanding: 52.0M.

  • Trailing P/E: 14.3×.

  • Forward dividend yield: 3944.17%, paying out 0% of earnings.

  • Rafael Holdings, Inc. employs 21 people — $47K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

RFL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelReal Estate Services
CompanyMarket capTKN rank
RFLRafael Holdings, Inc.$67.6M43
ASPSAltisource Portfolio Solutions SA$62.3M50
MAYSJ.W. Mays, Inc.$78.9M32
STHOStar Holdings$91.0M93
SRGSeritage Growth Properties$91.8M57
EUDAEUDA Health Holdings Ltd.$40.0M8
DOUGDouglas Elliman, Inc.$136.4M87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rafael Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RFL news & analysis

Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

MarketBeat · 4 Oct 2026negative

Rafael Holdings reported top-line results from its pivotal Phase III TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C, noting the study missed its primary endpoint. The company said it remains on track to submit a New Drug Application to the FDA in the fourth quarter of 2026.

Why it matters — The failure of the pivotal Phase III trial to meet its primary endpoint is a significant setback for Rafael's lead drug candidate and raises uncertainty around its development and regulatory path.

Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript

Seeking Alpha · 30 Sept 2026neutral

Rafael Holdings, Inc. (RFL) discussed the topline results of the Phase III TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C, according to a Seeking Alpha transcript of the discussion.

Why it matters — A watcher of RFL would care because the Phase III results of its Trappsol Cyclo candidate represent a key clinical milestone for the company's pipeline.

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

GlobeNewsWire · 30 Sept 2026neutral

Rafael Holdings announced topline results from its Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C. The drug did not reach statistical significance on the primary endpoint, though a prespecified analysis in patients on background miglustat/leucine therapy showed a statistically significant effect, and the safety profile was well-tolerated. The company remains on track to submit an NDA in Q4 2026.

Why it matters — RFL watchers would care because the pivotal Phase 3 results and the still-planned NDA submission in Q4 2026 are key determinants of the commercial path for Trappsol Cyclo, the company's lead asset.

FAQ

Frequently asked questions about RFL stock

How does Ticker Nerd's model rank RFL?

As at 22 Oct 2026, Rafael Holdings, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

What is the RFL stock forecast for 2030?

No analyst covering Rafael Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RFL are extrapolating price history, which says nothing about the business.

How has RFL stock performed over the past year?

Rafael Holdings, Inc. returned -7.2% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rafael Holdings, Inc. do?

Rafael Holdings Inc. Class B Common Stock is an equity security representing ownership in Rafael Holdings, a company focused on healthcare-related investments and operations.

What is the latest news on RFL?

The most recent item we track (MarketBeat, 4 Oct 2026): "Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing". Rafael Holdings reported top-line results from its pivotal Phase III TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C, noting the study missed its primary endpoint. The company said it remains on track to submit a New Drug Application to the FDA in the fourth quarter of 2026.

Company

About Rafael Holdings, Inc.

Rafael Holdings Inc. Class B Common Stock is an equity security representing ownership in Rafael Holdings, a company focused on healthcare-related investments and operations. The company is primarily involved in clinical and early-stage pharmaceutical interests, including oncology-oriented drug development, as well as medical devices and infusion technology activities. Its current business is organized across Healthcare, Infusion Technology, and Real Estate segments, giving it exposure to both life sciences and commercial property assets. Rafael Holdings also holds interests in companies working on therapies that target metabolic differences between normal and cancer cells, which places it within the specialized biopharmaceutical landscape. Headquartered in Newark, New Jersey, Rafael Holdings serves as a publicly traded vehicle for investors seeking exposure to a diversified mix of healthcare innovation and real estate holdings.

CEO Mr. Howard S. Jonas · 21 employees · United States · https://www.rafaelholdings.com